Current Month 2007
Article Features
  Study Finds Blocking Angiogenesis Signaling from Inside Cell May Lead to Serious Health Problems
Blood Transfusions are Unlikely to Spread Cancer
Pioneering Genetic Research on Ductal Carcinoma in Situ
Dense Breasts, Hormone Levels are Two Separate, Independent Risk Factors for Breast Cancer
Unlocking the Mechanisms that Silence the Estrogen Receptor Gene Alpha During Breast Cancer
Researchers Identify Gene Involved in Aggressive Form of Breast Cancer
New Study Suggests Concord Grape Juice May Provide Protection Against Breast Cancer
Green Tea Boosts Production of Detox Enzymes to Defend Against Breast Cancer
Hormone Therapy and Mammography Use Influence Breast Cancer Rates
Postmenopausal Sex Hormones and Breast Density Are Each Associated with Breast Cancer Risk
Questions that race through the minds of a woman facing a Cancer Situation
Male Breast Cancer
Additional Mammogram Readers Improve Breast Cancer Detection
Yearly Mammograms Protect Breast Cancer Survivors
MRI Finds Early-Stage Breast Cancer Before it Becomes Dangerous
Screening MRI Allows Detection of More Breast Cancers in High-Risk Women
Survey Finds Many Americans Believe Unsubstantiated Claims About Cancer
Gold Nanoparticles May Pan Out as Tool for Cancer Diagnosis
Study Finds Support Groups Improve Quality of Life for Metastatic Breast Cancer Patients But May Not Extend Survival
Tumors Use Enzyme to Recruit Regulatory T-cells and Suppress Immune Response
Study Shines More Light on Benefit of Vitamin D in Fighting Cancer


New Cause of Tamoxifen Resistance in Breast Cancer Cells Discovered

When a woman receives a breast cancer diagnosis her entire life may change in the blink of an eye. But the nature of that change is governed by the smallest alterations that take place within the proteins of the tumor cells, determining what treatments she can pursue with a hope of cure and those to which her cancer is resistant.

Scientists from the Georgetown University Medical Center's Lombardi Comprehensive Cancer Center have announced the discovery of a new mechanism of resistance to endocrine or anti-hormonal therapies, such as Tamoxifen and Faslodex. This research may allow oncologists to screen women for responsiveness to these treatments, and provides a much-needed clue to reversing resistance. The research, led by Robert Clark, PhD, DSc, a professor of oncology and of physiology and biophysics at Georgetown University Medical Center, indicates that a gene previously thought to be unrelated to breast cancer may be responsible for some resistance to endocrine therapy.

The gene, called human X-box binding protein-1 (XBP1), is an alternatively spliced transcription factor that participates in a stress-signaling pathway to protect cells from damage. In a paper published online in the Journal of the Federation of American Societies for Experimental Biology, Clarke and his colleagues at the Lombardi Comprehensive Cancer Center (part of Georgetown University Medical Center) found that over-expression of the spliced variant of the gene in estrogen receptor-positive breast cancer cells led to reduced sensitivity to Tamoxifen and Faslodex.

Read More of the Main Article

 
Visit the Ezine


Visit the BreastCenter

Visit the Quality Corner
Avon Breast Cancer Crusade - AVON the company for women

  This website is supported in part by an unrestricted educational grant provided by Avon